Senores Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 16 May 2025
Result Summary
- Senores Pharmaceuticals Ltd reported a 100.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were up by 119.4% QoQ and - - YoY.
- The net profit increased 99.0% QoQ and - - YoY.
- The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 12.2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 217.34 | 108.18 | 0.00 | 100.9% | - |
Total Expenses | 192.41 | 87.69 | 0.00 | 119.4% | - |
Profit Before Tax | 24.93 | 20.49 | - | 21.7% | NaN% |
Tax | -7.77 | 4.06 | 0.00 | -291.4% | - |
Profit After Tax | 32.70 | 16.43 | 0.00 | 99.0% | - |
Earnings Per Share | 12.20 | 5.00 | 0.00 | 144.0% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Senores Pharmaceuticals Ltd is a company operating in the pharmaceutical industry. The company is primarily engaged in the development, manufacturing, and marketing of pharmaceutical products. While specific details about the company's main products or recent developments are not provided in the data available for this report, it is known that companies in this sector typically focus on producing generic drugs, active pharmaceutical ingredients (APIs), and formulations. Furthermore, the pharmaceutical industry is characterized by rigorous regulatory standards, ongoing research and development, and a continuous need for innovation to address healthcare challenges. Without additional specific information, further insights into Senores Pharmaceuticals Ltd's unique market position, competitive landscape, or strategic initiatives remain unavailable.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Senores Pharmaceuticals Ltd reported a total income of ₹217.34 crores. This represents a significant increase of 100.9% compared to the previous quarter (Q3FY25), where the total income was ₹108.18 crores. The comparison to the fourth quarter of the previous fiscal year (Q4FY24) is not possible as the data for that period is not available. The notable quarter-over-quarter growth in revenue could indicate a strong performance in the recent quarter, reflecting either an increase in sales volume, price adjustments, or the introduction of new products or services. However, without explicit details about the company's product lines or market strategy, further specifics about the drivers of this revenue growth are not ascertainable.
Profitability
Senores Pharmaceuticals Ltd's profitability metrics for Q4FY25 show a positive trend compared to the previous quarter. The company reported a profit before tax of ₹24.93 crores, up 21.7% from ₹20.49 crores in Q3FY25. After accounting for taxes, the profit after tax increased substantially to ₹32.70 crores, a 99.0% rise from ₹16.43 crores in the prior quarter. This increase in profitability could be attributed to improved operational efficiencies, cost management, or favorable tax adjustments. The earnings per share (EPS) also saw a significant rise from ₹5.00 in Q3FY25 to ₹12.20 in Q4FY25, reflecting a 144.0% increase. The absence of data for the previous fiscal year's corresponding quarter prevents a year-over-year comparison of profitability metrics.
Operating Metrics
Analyzing the operating metrics, Senores Pharmaceuticals Ltd experienced an increase in total expenses for Q4FY25, which amounted to ₹192.41 crores, compared to ₹87.69 crores in Q3FY25, marking a 119.4% rise. This substantial increase in expenses could suggest heightened activity levels or investments in operational capacities. The tax component also shows a significant change, with a tax reversal of ₹7.77 crores in Q4FY25 compared to a tax expense of ₹4.06 crores in Q3FY25, indicating a 291.4% change. These financial movements are crucial for understanding the company's operational efficiency and cost structure, though the lack of detailed breakdowns or specific operational data limits the depth of analysis. Overall, the key operating metrics indicate a period of significant financial activity, with the company experiencing both increased revenues and expenses.